Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.61 |
| ▸ | AURKA | O14965 | 3/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.59 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.59 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | CHUK | O15111 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 6/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.50 |
| ▸ | PAK4 | O96013 | 3/20 | 0.50 |
| ▸ | CSF1R | P07333 | 3/20 | 0.50 |
| ▸ | RET | P07949 | 3/20 | 0.50 |
| ▸ | MET | P08581 | 3/20 | 0.50 |
| ▸ | PIM1 | P11309 | 3/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.50 |
| ▸ | PRKACA | P17612 | 3/20 | 0.50 |
| ▸ | FLT1 | P17948 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29541277 | 1.00 | JAK2 (0.61) | JAK2AURKAAURKBINCENPTPX2 | |
| SCHEMBL4006751 | 0.76 | JAK2 (1.00) | JAK2AURKAAURKBBRD4IKBKB | |
| SCHEMBL4115515 | 0.75 | JAK2 (0.54) | JAK2AURKAAURKBBRD4IKBKB | |
| SCHEMBL4116922 | 0.75 | JAK2 (0.57) | JAK2AURKAAURKBBRD4IKBKB | |
| SCHEMBL13695900 | 0.75 | BRD4 (0.54) | JAK2AURKAAURKBBRD4IKBKB | |
| SCHEMBL13765436 | 0.75 | JAK2 (0.72) | JAK2AURKAAURKBBRD4IKBKB | |
| SCHEMBL2239177 | 0.74 | AURKB (1.00) | JAK2AURKAAURKBINCENPTPX2 | |
| SCHEMBL31061291 | 0.74 | AURKB (1.00) | JAK2AURKAAURKBINCENPTPX2 | |
| SCHEMBL25837844 | 0.74 | AURKA (0.55) | JAK2AURKAAURKBINCENPTPX2 | |
| SCHEMBL4582353 | 0.73 | JAK2 (0.70) | JAK2AURKAAURKBBRD4IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658274-A1 | CRYSTALLINE FORM OF DEURUXOLITINIB | SUN PHARMACEUTICAL INDUSTRIES, INC. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250326762-A1 | CRYSTALLINE FORM OF DEURUXOLITINIB | SUN PHARMACEUTICAL IND INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| US-12247034-B1 | Crystalline form of deuruxolitinib phosphate | SUN PHARMACEUTICAL INDUSTRIES, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4501410-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119306753-A | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3272738-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-108395433-B | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-3452039-B1 | TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | SUN PHARMACEUTICAL IND INC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-2343299-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110086810-A1 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086810-A1 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2011-04-14 | — | — | US | disclosed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | disclosed |
| WO-2010083283-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20090227607-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090227607-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-02 | — | — | US | disclosed |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-02 | — | — | US | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | JAK2 2515/4885AURKA 727/4885AURKB 1133/4885 |
| US-20250326762-A1 | CRYSTALLINE FORM OF DEURUXOLITINIB | JAK1, CDK4, JAK3 | JAK2 12/4885AURKA 1377/4885AURKB 1560/4885 |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | JAK2 3/4885AURKA 289/4885AURKB 455/4885 |
| US-20110086810-A1 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | UGT1A4, UGT1A3, UGT1A1 | JAK2 3506/4885AURKA 1265/4885AURKB 1378/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | JAK2 3/4885AURKA 345/4885AURKB 498/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | JAK2 3/4885AURKA 345/4885AURKB 498/4885 |
| US-12247034-B1 | Crystalline form of deuruxolitinib phosphate | JAK1, PRKDC, PTPN4 | JAK2 15/4885AURKA 1384/4885AURKB 1661/4885 |
| US-20090227607-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | JAK2 3/4885AURKA 289/4885AURKB 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.